Myeloma bone disease is characterized by osteolytic destruction associated with suppressed osteoblastic activity. Using data from the APEX (Richardson et al., N Engl J Med 2005;352:2487-2498) study, we have assessed the relationship of changes in alkaline phosphatase (ALP) levels during bortezomib therapy with response and time to progression on this therapy. The percentage of ALP increments in responders (complete and partial response) and nonresponders was analyzed at different thresholds and time points. For all bortezomib-treated patients enrolled in the trial (N = 333), at least a 25% increase in ALP from the baseline at 6 week was the most powerful predictor of treatment response (P < 0.0001) and time to progression (206 vs. 169 days) relative to patients with less than a 25% increase in ALP (P = 0.01). Markers of osteoblastic activation may predict quality and duration of response in multiple myeloma. In addition, our data suggest that bone anabolism could inhibit myeloma growth.,
American Journal of Hematology
Erasmus MC: University Medical Center Rotterdam

Zangari, M., Esseltine, D.-L., Cavallo, F., Neuwirth, R., Elice, F., Burns, M., … Tricot, G. (2007). Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. American Journal of Hematology, 82(9), 831–833. doi:10.1002/ajh.20961